Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
N Engl J Med. 2020.
PMID: 32101663
Clinical Trial.